Article

Gabapentinimproves sleep in the presence of alcohol

Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine (Impact Factor: 2.83). 08/2005; 1(3):284-7.
Source: PubMed

ABSTRACT To evaluate the ability of a single dose of gabapentin to improve sleep disruption caused by alcohol consumption.
Double-blind, randomized, single-dose, crossover study of normal subjects (age 21-45 years) who were free of known sleep disorders or medical conditions that could interfere with sleep. Subjects first received baseline polysomnography and, upon awakening, subjective scales of drowsiness and functioning. One to 2 weeks later, they returned to the sleep lab. They consumed 4 ounces of 40% alcohol and gabapentin (300 or 600 mg) or placebo 1 hour prior to bedtime. Polysomnography and subjective scales were repeated. One to 2 weeks later, subjects returned and were given the same dose of alcohol and the other treatment, followed by repeat testing. Differences between baseline and placebo (alcohol) results were compared to the difference between baseline and gabapentin (alcohol) by paired t tests.
Thirteen subjects were enrolled; 12 completed the study. Mean age was 30.8 years (range 25-37 years). No difference in total sleep time was seen for any of the groups. Gabapentin (300 or 600 mg) showed a significant decrease in stage 1 (9.3% vs 5.5%) and number of awakenings (11 vs 6) with increased sleep efficiency (93% vs 96.2%). Subjects receiving 600 mg also showed increased slow wave sleep, decreased rapid eye movement sleep, and decreased arousals. No differences were seen in any of the subjective tests of drowsiness and performance.
Single-dose gabapentin at bedtime can improve sleep through decreased stage 1 sleep, increased slow-wave sleep, increased sleep efficiency, and decreased arousals. Gabapentin may be useful in the treatment of conditions in which frequent awakenings and decreased sleep efficiency are seen.

0 Followers
 · 
122 Views
  • Source
    • "By contrast, studies of gabapentin to treat acute alcohol withdrawal reveal mixed results (Bonnet et al., 2003, 2007; Mariani et al., 2006; Voris et al., 2003). The potential efficacy of gabapentin to prevent relapse is particularly notable because it has low addictive potential (with some recently reported exceptions [Pittenger and Desan, 2007; Victorri- Vigneau et al., 2007]), does not undergo hepatic metabolism and has few interactions with other medications (Beydoun et al., 1995), is relatively safe when combined with alcohol (Bazil et al., 2005; Bisaga and Evans, 2006; Myrick et al., 2007), and is not associated with fatal overdoses when taken alone (Klein-Schwartz et al., 2003) Gabapentin was also safe and well-tolerated in this study. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Insomnia and other sleep disturbances are common, persistent, and associated with relapse in alcohol-dependent patients. The purpose of this pilot study was to compare gabapentin versus placebo for the treatment of insomnia and prevention of relapse in alcohol-dependent patients. Twenty-one subjects, including 10 women who met study criteria for alcohol dependence and insomnia and expressed a desire to abstain from alcohol, were recruited to the study. During a 1 to 2 week placebo lead-in and screening phase, a complete medical history, physical exam, blood tests, urine drug test, and structured interviews were performed to determine eligibility and patterns of alcohol use and sleep. Insomnia due to intoxication or acute withdrawal, psychiatric or medical illness, medications, and other sleep disorders were ruled out. Subjects were then randomized to either placebo (n = 11) or gabapentin (n = 10) for 6 weeks and titrated over a 10-day period to 1,500 mg or 5 pills at bedtime. After a 4-day taper, subjects were reassessed 6 weeks after ending treatment. Gabapentin significantly delayed the onset to heavy drinking, an effect which persisted for 6 weeks after treatment ended. Insomnia improved in both treatment groups during the medication phase, but gabapentin had no differential effects on sleep as measured by either subjective report or polysomnography. Because gabapentin is a short-acting medication that was taken only at nighttime in this study, it may possibly exert a nocturnal effect that prevents relapse to heavy drinking by a physiological mechanism not measured in this pilot study.
    Alcoholism Clinical and Experimental Research 07/2008; 32(8):1429-38. DOI:10.1111/j.1530-0277.2008.00706.x · 3.31 Impact Factor
  • Source
    • "A limited number of studies have suggested that these compounds may improve sleep maintenance, by significantly impacting measures of SWS, NAW, and REM sleep [284] [285]. However, a trial involving 3 nights of pregabalin administration found evidence of significant rebound impairment in almost every PSG parameter following treatment discontinuation [284]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Insomnia is a common condition that often is co-morbid with other illnesses. It is associated with significant morbidities, including nighttime distress, impaired cognitive functioning, impaired daytime functioning, and increased risk of accidents. People with insomnia utilize healthcare services more often than those without insomnia, and they are at greater risk for the development of certain health problems; most notably psychiatric illness such as depression. It is now known that the significant impact of insomnia warrants diagnosis and treatment. Behavioral and psychopharmacological treatments have been available for some time. However, formerly common classes of therapeutics such as the barbiturates and benzodiazepines have been replaced by new allosteric modulators of the GABA(A) receptor and other therapeutics with novel mechanisms of action. This article presents existing approaches to insomnia treatment, and reviews new treatments, therapeutic targets, and treatment approaches to insomnia under development that may offer promise to practitioners and patients.
    CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders) 03/2007; 6(1):3-16. DOI:10.2174/187152707779940754 · 2.70 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The benzodiazepine binding site on the GABAA receptor is the target for the majority of hypnotics, including the nonbenzodiazepine ‘Z drugs’ (zaleplon, zolpidem, zopiclone and eszopiclone). Concerns still exist over long-term benzodiazepine use, and efforts are, therefore, being made to search for new hypnotic agents and alternative receptor target sites, with novel mechanisms of action. Clinically useful compounds, including GABA mimetics and GABA-uptake inhibitors, have been found by developing structurally rigid analogs of GABA. The GABA-site agonist 4,5,6,7-tetra hydroisoxazolo[5,4-c]pyridin-3-ol (THIP) shows high potency for extrasynaptic GABAA receptor subtypes, which are not primary targets for classical benzodiazepines or the Z drugs. Hence, THIP targets a novel set of GABAA receptors. The antiepileptic drug, tiagabine, is a specific blocker of the GAT-1 GABA-transporter, increasing GABA levels following synaptic GABA release. It is proposed that this promotes extrasynaptic GABAA receptor activity. In contrast, two other GABA analogs, pregabalin and gabapentin, are not GABA mimetics but appear to act at calcium channels responsible for neurotransmitter release, rather than at the GABA receptors. All of these GABA analogs modify sleep behaviors and so are potentially effective hypnotic drugs that provide an alternative to the benzodiazepine binding site of the GABAA receptor.
    Sleep Medicine 08/2006; 7(1). DOI:10.1016/j.sleep.2006.03.001 · 3.10 Impact Factor
Show more

Preview

Download
3 Downloads
Available from